Abstract
Despite the recent approval of novel immunotherapies, such as immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies, Multi......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
